Halozyme Therapeutics, Inc.(HALO)Earnings, Financials & Key Ratios

HALO•NASDAQ

$65.87

$7.76B mkt cap·25.7× P/E·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryDrug Delivery Technology Platforms

AboutHalozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.Show more

Revenue$1.4B+37.6%
EBITDA$904M+42.9%
Net Income$317M-28.6%
EPS (Diluted)2.56-25.4%
Gross Margin78.13%-7.3%
EBITDA Margin64.75%+3.9%
Operating Margin58.45%+7.6%
Net Margin22.69%-48.1%
ROE153.59%-22.6%
ROIC73.37%+185.5%
Interest Coverage45.03+47.8%

Technical→

HALO Key Insights

Halozyme Therapeutics, Inc. (HALO) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Excellent 3Y average ROE of 191.4%
✓Strong 5Y profit CAGR of 19.7%
✓FCF machine: 46.2% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 39.2%
✓Share count reduced 4.3% through buybacks

✗Weaknesses

✗Expensive at 167.2x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

HALO Price & Volume

Halozyme Therapeutics, Inc. (HALO) stock price & volume — 10-year historical chart

Loading chart...

HALO Growth Metrics

Halozyme Therapeutics, Inc. (HALO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years26.32%

5 Years39.16%

3 Years28.38%

TTM37.55%

Profit CAGR

10 Years-

5 Years19.68%

3 Years16.17%

TTM-28.64%

EPS CAGR

10 Years-

5 Years22.98%

3 Years21.14%

TTM-27.41%

Return on Capital

10 Years14.1%

5 Years31.52%

3 Years29.86%

Last Year38.21%

HALO Recent Earnings

Halozyme Therapeutics, Inc. (HALO) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 9/12 qtrs (75%)●Beat Revenue 4/12 qtrs (33%)

Q1 2026Latest

Feb 17, 2026

EPS

$0.24

Est $2.15

-111.2%

Revenue

$452M

Est $436M

+3.7%

Q4 2025

Nov 3, 2025

EPS

$1.72

Est $1.63

+5.5%

Revenue

$354M

Est $447M

-20.7%

Q3 2025

Aug 5, 2025

EPS

$1.54

Est $1.23

+25.2%

Revenue

$326M

Est $331M

-1.5%

Q2 2025

May 6, 2025

EPS

$1.11

Est $0.95

+16.8%

Revenue

$265M

Est $281M

-5.7%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 17, 2026	$0.24vs $2.15-111.2%	$452Mvs $436M+3.7%
Q4 2025	Nov 3, 2025	$1.72vs $1.63+5.5%	$354Mvs $447M-20.7%
Q3 2025	Aug 5, 2025	$1.54vs $1.23+25.2%	$326Mvs $331M-1.5%
Q2 2025	May 6, 2025	$1.11vs $0.95+16.8%	$265Mvs $281M-5.7%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
ALNYAlnylam Pharmaceuticals, Inc.Direct Competitor	40.18B	301.11	129.23	65.19%	13.46%	98.29%	1.16%	1.62
IONSIonis Pharmaceuticals, Inc.Direct Competitor	12.44B	75.25	-31.62	33.87%	-30.87%	-58.57%		5.35
ARWRArrowhead Pharmaceuticals, Inc.Direct Competitor	10.49B	74.93	-6141.80	232.58%	18.54%	35.64%	1.5%	0.73
EXELExelixis, Inc.Direct Competitor	11.28B	44.42	15.98	6.98%	35.08%	40.21%	7.48%	0.08
INVAInnoviva, Inc.Direct Competitor	1.69B	22.65	6.86	18.52%	65.38%	23.12%	11.58%
RCUSArcus Biosciences, Inc.Direct Competitor	2.62B	26.06	-7.92	-4.26%	-156.36%	-68.97%		0.16
ABBVAbbVie Inc.Product Competitor	364.63B	206.15	86.98	8.57%	6.91%	62.15%	4.89%
AMGNAmgen Inc.Product Competitor	177.87B	329.59	23.16	9.92%	20.95%	89.41%	4.55%	6.31

Compare HALO vs Peers

Halozyme Therapeutics, Inc. (HALO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ALNY

Most directly comparable listed peer for HALO.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare HALO against a more recognizable public peer.

Peer Set

Compare Top 5

vs ALNY, IONS, ARWR, EXEL

HALO Income Statement

Halozyme Therapeutics, Inc. (HALO) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	316.61M	151.86M	195.99M	267.59M	443.31M	660.12M	829.25M	1.02B	1.4B
Revenue Growth %	115.84%	-52.04%	29.06%	36.53%	65.67%	48.91%	25.62%	22.44%	37.55%
Cost of Goods Sold	31.15M	10.14M	45.55M	43.37M	81.41M	139.3M	192.36M	159.42M	305.44M
COGS % of Revenue	9.84%	6.67%	23.24%	16.21%	18.36%	21.1%	23.2%	15.7%	21.87%
Gross Profit	285.46M▲ 0%	141.73M▼ 50.4%	150.45M▲ 6.2%	224.23M▲ 49.0%	361.9M▲ 61.4%	520.81M▲ 43.9%	636.89M▲ 22.3%	855.91M▲ 34.4%	1.09B▲ 27.5%
Gross Margin %	90.16%	93.33%	76.76%	83.79%	81.64%	78.9%	76.8%	84.3%	78.13%
Gross Profit Growth %	151.54%	-50.35%	6.15%	49.04%	61.4%	43.91%	22.29%	34.39%	27.49%
Operating Expenses	204.46M	211.06M	218.06M	79.97M	86M	253.28M	299.32M	304.43M	274.88M
OpEx % of Revenue	64.58%	138.98%	111.26%	29.89%	19.4%	38.37%	36.09%	29.98%	19.68%
Selling, General & Admin	53.82M	60.8M	77.25M	45.74M	50.32M	143.53M	149.18M	154.34M	193.39M
SG&A % of Revenue	17%	40.04%	39.42%	17.09%	11.35%	21.74%	17.99%	15.2%	13.85%
Research & Development	150.64M	150.25M	140.8M	34.24M	35.67M	66.61M	76.36M	79.05M	81.49M
R&D % of Revenue	47.58%	98.94%	71.84%	12.79%	8.05%	10.09%	9.21%	7.79%	5.83%
Other Operating Expenses	0	0	0	0	0	43.15M	73.77M	71.05M	0
Operating Income	81M▲ 0%	-69.33M▼ 185.6%	-67.61M▲ 2.5%	144.25M▲ 313.4%	275.9M▲ 91.3%	267.53M▼ 3.0%	337.57M▲ 26.2%	551.48M▲ 63.4%	816.29M▲ 48.0%
Operating Margin %	25.58%	-45.65%	-34.5%	53.91%	62.24%	40.53%	40.71%	54.32%	58.45%
Operating Income Growth %	197.35%	-185.59%	2.48%	313.36%	91.26%	-3.03%	26.18%	63.36%	48.02%
EBITDA	83.16M	-66.94M	-63.54M	147.54M	278.9M	317.17M	422.43M	632.79M	904.34M
EBITDA Margin %	26.27%	-44.08%	-32.42%	55.14%	62.91%	48.05%	50.94%	62.32%	64.75%
EBITDA Growth %	202.92%	-180.49%	5.08%	332.19%	89.03%	13.72%	33.19%	49.8%	42.91%
D&A (Non-Cash Add-back)	2.16M	2.39M	4.07M	3.28M	3M	49.64M	84.86M	81.31M	88.05M
EBIT	81M	-69.33M	-60.62M	149.68M	256.04M	265.87M	367.09M	575.23M	816.29M
Net Interest Income	-21.98M	-18.04M	-11.63M	-20.38M	-7.53M	-16.95M	-18.76M	-18.09M	-18.13M
Interest Income	0	0	0	0	0	0	0	0	0
Interest Expense	21.98M	18.04M	11.63M	20.38M	7.53M	16.95M	18.76M	18.09M	18.13M
Other Income/Expense	-19.39M	-10.46M	-4.64M	-14.95M	-27.38M	-18.61M	10.76M	5.66M	-349.42M
Pretax Income	61.61M▲ 0%	-79.79M▼ 229.5%	-72.25M▲ 9.5%	129.3M▲ 279.0%	248.52M▲ 92.2%	248.92M▲ 0.2%	348.33M▲ 39.9%	557.13M▲ 59.9%	466.88M▼ 16.2%
Pretax Margin %	19.46%	-52.54%	-36.86%	48.32%	56.06%	37.71%	42.01%	54.87%	33.43%
Income Tax	-1.36M	537K	-11K	217K	-154.19M	46.79M	66.73M	113.04M	149.99M
Effective Tax Rate %	-2.21%	-0.67%	0.02%	0.17%	-62.04%	18.8%	19.16%	20.29%	32.13%
Net Income	62.97M▲ 0%	-80.33M▼ 227.6%	-72.24M▲ 10.1%	129.09M▲ 278.7%	402.71M▲ 212.0%	202.13M▼ 49.8%	281.59M▲ 39.3%	444.09M▲ 57.7%	316.89M▼ 28.6%
Net Margin %	19.89%	-52.9%	-36.86%	48.24%	90.84%	30.62%	33.96%	43.74%	22.69%
Net Income Growth %	161.12%	-227.57%	10.07%	278.69%	211.97%	-49.81%	39.31%	57.71%	-28.64%
Net Income (Continuing)	62.97M	-80.33M	-72.24M	129.09M	402.71M	202.13M	281.59M	444.09M	316.89M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	0.45▲ 0%	-0.56▼ 224.4%	-0.50▲ 10.7%	0.91▲ 282.0%	2.74▲ 201.1%	1.44▼ 47.4%	2.10▲ 45.8%	3.43▲ 63.3%	2.56▼ 25.4%
EPS Growth %	155.56%	-224.44%	10.71%	282%	201.1%	-47.45%	45.83%	63.33%	-25.36%
EPS (Basic)	0.46	-0.56	-0.50	0.95	2.86	1.48	2.13	3.50	2.64
Diluted Shares Outstanding	139.07M	143.6M	144.33M	141.46M	146.8M	140.61M	134.2M	129.42M	123.9M
Basic Shares Outstanding	136.42M	143.45M	144.33M	136.21M	140.65M	136.84M	131.93M	126.83M	119.84M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

HALO Balance Sheet

Halozyme Therapeutics, Inc. (HALO) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	510.37M	427.85M	543.44M	554.76M	926.29M	739.01M	746.42M	1.09B	825.21M
Cash & Short-Term Investments	469.21M	354.53M	421.26M	368.01M	740.92M	362.79M	336M	596.07M	142.82M
Cash Only	168.74M	57.94M	120.18M	147.7M	118.72M	234.19M	118.37M	115.85M	133.82M
Short-Term Investments	300.47M	296.59M	301.08M	220.31M	622.2M	128.6M	217.63M	480.22M	9M
Accounts Receivable	22.13M	30M	59.44M	97.73M	90.97M	231.07M	234.21M	308.45M	441.27M
Days Sales Outstanding	25.52	72.12	110.7	133.3	74.9	127.77	103.09	110.89	115.33
Inventory	5.15M	22.63M	29.36M	60.75M	53.91M	100.12M	127.6M	141.86M	176.47M
Days Inventory Outstanding	60.29	814.73	235.28	511.28	241.69	262.34	242.12	324.8	210.89
Other Current Assets	0	0	0	0	0	45.02M	48.61M	38.95M	64.64M
Total Non-Current Assets	9.57M	12.4M	22.44M	25.16M	178.14M	1.1B	986.85M	978.14M	1.7B
Property, Plant & Equipment	3.52M	7.46M	10.86M	10.59M	8.79M	75.57M	74.94M	75.03M	82.14M
Fixed Asset Turnover	89.95x	20.34x	18.06x	25.26x	50.41x	8.74x	11.06x	13.53x	17.00x
Goodwill	0	0	0	0	0	409.05M	416.82M	416.82M	580.36M
Intangible Assets	0	0	0	0	0	546.65M	472.88M	401.83M	981.47M
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	6.05M	4.93M	11.58M	14.57M	13.91M	26.8M	17.82M	80.6M	56.15M
Total Assets	519.95M▲ 0%	440.25M▼ 15.3%	565.87M▲ 28.5%	579.92M▲ 2.5%	1.1B▲ 90.4%	1.84B▲ 66.7%	1.73B▼ 5.9%	2.06B▲ 19.1%	2.53B▲ 22.4%
Asset Turnover	0.61x	0.34x	0.35x	0.46x	0.40x	0.36x	0.48x	0.49x	0.55x
Asset Growth %	98.82%	-15.33%	28.54%	2.48%	90.44%	66.74%	-5.88%	19.05%	22.38%
Total Current Liabilities	131.33M	149.36M	85.64M	421.38M	117.15M	130.79M	112.49M	139.1M	177.09M
Accounts Payable	7.95M	4.08M	6.43M	1.93M	1.54M	17.69M	11.82M	10.25M	20.9M
Days Payables Outstanding	93.12	146.89	51.56	16.23	6.91	46.36	22.42	23.47	24.97
Short-Term Debt	77.21M	91.51M	19.54M	397.23M	89.42M	13.33M	0	0	0
Deferred Revenue (Current)	6.57M	4.25M	4.01M	1.75M	1.75M	3.25M	0	0	0
Other Current Liabilities	0	0	0	0	0	-3.25M	0	0	156.19M
Current Ratio	3.89x	2.86x	6.35x	1.32x	7.91x	5.65x	6.64x	7.80x	4.66x
Quick Ratio	3.85x	2.71x	6.00x	1.17x	7.45x	4.88x	5.50x	6.78x	3.66x
Cash Conversion Cycle	-7.31	739.96	294.42	628.36	309.68	343.75	322.79	412.22	301.24
Total Non-Current Liabilities	180.25M	42M	388.47M	7.49M	790.33M	1.54B	1.54B	1.56B	2.3B
Long-Term Debt	125.14M	34.87M	383.05M	0	787.25M	1.49B	1.5B	1.51B	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	42.92M
Other Non-Current Liabilities	814K	2.12M	4.18M	3.47M	544K	45.91M	37.72M	54.76M	2.26B
Total Liabilities	311.58M	191.36M	474.11M	428.88M	907.48M	1.67B	1.65B	1.7B	2.48B
Total Debt	202.35M	126.38M	402.59M	397.23M	876.67M	1.51B	1.5B	1.51B	0
Net Debt	33.61M	68.44M	282.41M	249.53M	757.96M	1.27B	1.38B	1.39B	-133.82M
Debt / Equity	0.97x	0.51x	4.39x	2.63x	4.45x	8.87x	17.89x	4.14x	-
Debt / EBITDA	2.43x	-	-	2.69x	3.14x	4.75x	3.55x	2.38x	-
Net Debt / EBITDA	0.40x	-	-	1.69x	2.72x	4.01x	3.27x	2.20x	-0.15x
Interest Coverage	3.68x	-3.84x	-5.81x	7.08x	36.66x	15.79x	17.99x	30.48x	45.03x
Total Equity	208.37M▲ 0%	248.89M▲ 19.4%	91.77M▼ 63.1%	151.05M▲ 64.6%	196.95M▲ 30.4%	169.8M▼ 13.8%	83.81M▼ 50.6%	363.82M▲ 334.1%	48.81M▼ 86.6%
Equity Growth %	741.5%	19.45%	-63.13%	64.6%	30.39%	-13.79%	-50.64%	334.11%	-86.58%
Book Value per Share	1.50	1.73	0.64	1.07	1.34	1.21	0.62	2.81	0.39
Total Shareholders' Equity	208.37M	248.89M	91.77M	151.05M	196.95M	169.8M	83.81M	363.82M	48.81M
Common Stock	143K	145K	137K	135K	138K	135K	127K	123K	118K
Retained Earnings	-522.37M	-531.44M	-603.68M	-474.59M	-58.91M	143.22M	90.55M	359.87M	54.79M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-450K	-277K	240K	22K	-620K	-922K	-9.28M	3.83M	-18.09M
Minority Interest	0	0	0	0	0	0	0	0	0

HALO Cash Flow Statement

Halozyme Therapeutics, Inc. (HALO) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	134.05M	-49.5M	-85.42M	55.45M	299.44M	240.11M	388.57M	479.06M	651.56M
Operating CF Margin %	42.34%	-32.6%	-43.58%	20.72%	67.55%	36.37%	46.86%	47.18%	46.65%
Operating CF Growth %	366.07%	-136.93%	-72.57%	164.92%	439.98%	-19.81%	61.83%	23.29%	36.01%
Net Income	62.97M	-80.33M	-72.24M	129.09M	402.71M	202.13M	281.59M	444.09M	316.89M
Depreciation & Amortization	2.16M	2.39M	6.55M	17.42M	6.64M	57.48M	84.86M	88.66M	88.05M
Stock-Based Compensation	30.67M	35.7M	34.78M	17.2M	20.82M	24.4M	36.62M	43.38M	51.56M
Deferred Taxes	-257K	-3.08M	0	0	0	0	34.51M	0	634K
Other Non-Cash Items	17.82M	1.7M	666K	-41.1M	-133.3M	66.59M	-10.33M	39.2M	346.68M
Working Capital Changes	20.69M	-5.87M	-55.18M	-67.16M	2.57M	-110.49M	-38.67M	-136.27M	-152.26M
Change in Receivables	-6.45M	11.61M	-29.44M	-38.29M	6.75M	-83.94M	-3.34M	-74.25M	-128.06M
Change in Inventory	9.48M	-17.48M	-6.73M	-31.39M	7.37M	-17.48M	-26.88M	-67.38M	2.55M
Change in Payables	15.63M	-278.49M	0	0	0	0	-12.55M	0	0
Cash from Investing	-163.73M	2.49M	-5.55M	78.35M	-406.29M	-487M	-96.91M	-262.72M	-545.81M
Capital Expenditures	-1.35M	-4.66M	-4.04M	-2.5M	-1.46M	-4.81M	-15.29M	-10.7M	-6.97M
CapEx % of Revenue	0.43%	3.07%	2.06%	0.94%	0.33%	0.73%	1.84%	1.05%	0.5%
Acquisitions	0	0	0	0	0	-999.12M	0	0	-725.97M
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-162.38M	7.16M	-1.51M	80.86M	-404.83M	516.92M	0	-252.03M	-287.77M
Cash from Financing	131.66M	-63.8M	153.22M	-106.28M	77.86M	362.37M	-407.99M	-218.86M	-85.17M
Debt Issued (Net)	-15.99M	-77.52M	339.27M	-19.56M	415.81M	624.55M	-13.48M	0	235.37M
Equity Issued (Net)	1000K	0	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K	-1000K
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	-200M	-150.12M	-350.06M	-200M	-402.38M	-250M	-342.37M
Other Financing	12.78M	13.72M	13.95M	63.39M	12.11M	-62.17M	7.88M	31.14M	0
Net Change in Cash	101.98M▲ 0%	-110.8M▼ 208.7%	62.24M▲ 156.2%	27.52M▼ 55.8%	-28.98M▼ 205.3%	115.48M▲ 498.4%	-116.33M▼ 200.7%	-2.52M▲ 97.8%	20.57M▲ 916.3%
Free Cash Flow	132.7M▲ 0%	-54.16M▼ 140.8%	-89.46M▼ 65.2%	52.95M▲ 159.2%	297.98M▲ 462.8%	235.3M▼ 21.0%	373.28M▲ 58.6%	468.37M▲ 25.5%	644.59M▲ 37.6%
FCF Margin %	41.91%	-35.67%	-45.65%	19.79%	67.22%	35.65%	45.01%	46.13%	46.15%
FCF Growth %	347.95%	-140.82%	-65.17%	159.19%	462.76%	-21.04%	58.64%	25.47%	37.62%
FCF per Share	0.95	-0.38	-0.62	0.37	2.03	1.67	2.78	3.62	5.20
FCF Conversion (FCF/Net Income)	2.13x	0.62x	1.18x	0.43x	0.74x	1.19x	1.38x	1.08x	2.06x
Interest Paid	20.3M	16.89M	9.03M	6.53M	3.3M	6.11M	11.41M	10.56M	0
Taxes Paid	3.02M	220K	0	0	0	0	31.76M	0	0

HALO Key Ratios

Halozyme Therapeutics, Inc. (HALO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-1958.98%	71.6%	-35.14%	-42.41%	106.33%	231.44%	110.23%	222.07%	198.42%	153.59%
Return on Invested Capital (ROIC)	-74.78%	33.81%	-18.59%	-14.67%	27.93%	30.53%	16.74%	17.42%	25.7%	73.37%
Gross Margin	77.36%	90.16%	93.33%	76.76%	83.79%	81.64%	78.9%	76.8%	84.3%	78.13%
Net Margin	-70.23%	19.89%	-52.9%	-36.86%	48.24%	90.84%	30.62%	33.96%	43.74%	22.69%
Debt / Equity	-	0.97x	0.51x	4.39x	2.63x	4.45x	8.87x	17.89x	4.14x	-
Interest Coverage	-4.17x	3.68x	-3.84x	-5.81x	7.08x	36.66x	15.79x	17.99x	30.48x	45.03x
FCF Conversion	0.49x	2.13x	0.62x	1.18x	0.43x	0.74x	1.19x	1.38x	1.08x	2.06x
Revenue Growth	8.61%	115.84%	-52.04%	29.06%	36.53%	65.67%	48.91%	25.62%	22.44%	37.55%

HALO SEC Filings & Documents

Halozyme Therapeutics, Inc. (HALO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Mar 12, 2026·SEC

Material company update

Feb 17, 2026·SEC

Material company update

Jan 28, 2026·SEC

10-K Annual Reports

FY 2026

Feb 17, 2026·SEC

FY 2025

Feb 18, 2025·SEC

FY 2024

Feb 20, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 3, 2025·SEC

FY 2025

Aug 5, 2025·SEC

FY 2025

May 6, 2025·SEC

HALO Frequently Asked Questions

Halozyme Therapeutics, Inc. (HALO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Halozyme Therapeutics, Inc. (HALO) reported $1.40B in revenue for fiscal year 2025. This represents a 5657631% increase from $0.0M in 2001.

Halozyme Therapeutics, Inc. (HALO) grew revenue by 37.6% over the past year. This is strong growth.

Yes, Halozyme Therapeutics, Inc. (HALO) is profitable, generating $316.9M in net income for fiscal year 2025 (22.7% net margin).

Dividend & Returns

Halozyme Therapeutics, Inc. (HALO) has a return on equity (ROE) of 153.6%. This is excellent, indicating efficient use of shareholder capital.

Halozyme Therapeutics, Inc. (HALO) generated $644.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More HALO

Halozyme Therapeutics, Inc. (HALO) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Halozyme Therapeutics, Inc.(HALO)Earnings, Financials & Key Ratios

HALO Key Insights

✓Strengths

✗Weaknesses

HALO Price & Volume

HALO Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

HALO Recent Earnings

HALO Peer Comparison

Compare HALO vs Peers

vs ALNY

vs JNJ

Compare Top 5

HALO Income Statement

HALO Balance Sheet

HALO Cash Flow Statement

HALO Key Ratios

HALO SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

HALO Frequently Asked Questions

Explore More HALO

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation